Currently, there are 1.15B common shares owned by the public and among those 1.15B shares have been available to trade.
The company’s stock has a 5-day price change of 4.05% and 6.62% over the past three months. TEVA shares are trading -19.65% year to date (YTD), with the 12-month market performance up to 4.92% higher. It has a 12-month low price of $12.47 and touched a high of $22.80 over the same period. TEVA has an average intraday trading volume of 12.26 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.38%, 13.65%, and 0.99% respectively.
Institutional ownership of Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) shares accounts for 62.98% of the company’s 1.15B shares outstanding.
It has a market capitalization of $20.29B and a beta (3y monthly) value of 0.61. The earnings-per-share (ttm) stands at -$1.14. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.50% over the week and 3.45% over the month.
Earnings per share for the fiscal year are expected to increase by 2.30%, and 8.35% over the next financial year. EPS should grow at an annualized rate of 7.26% over the next five years, compared to -9.62% over the past 5-year period.
Looking at the support for the TEVA, a number of firms have released research notes about the stock. JP Morgan stated their Overweight rating for the stock in a research note on May 12, 2025, with the firm’s price target at $23. Argus coverage for the Teva- Pharmaceutical Industries Ltd. ADR (TEVA) stock in a research note released on July 10, 2024 offered a Buy rating with a price target of $20. JP Morgan was of a view on March 08, 2024 that the stock is Neutral, while Piper Sandler gave the stock Overweight rating on February 12, 2024, issuing a price target of $12- $19. Jefferies on their part issued Buy rating on January 23, 2024.
